Immunology and Microbiology
Adaptive Immune System
12%
Adoptive Immunity
13%
Antigen Specificity
10%
Autoimmunity
10%
B Cell
14%
Bacilli
10%
Booster Dose
11%
COVID-19
17%
Dendritic Cell
20%
Extended Spectrum Beta Lactamase Producing Klebsiella Pneumoniae
20%
Food Allergy
10%
Gastrointestinal Tract
14%
Glycan
10%
Heme
10%
Homeostasis
31%
Human Metapneumovirus
10%
Humoral Immunity
17%
Immune Response
56%
Immunocompetent Cell
13%
Immunogenicity
29%
Immunoglobulin A
21%
Inactivated Vaccine
22%
Infectious Agent
13%
Inflammatory Arthritis
10%
Innate Lymphoid Cell
36%
interferon
17%
IRF8
10%
Lymph Node
12%
Lymphoid Tissue
46%
Microflora
24%
Monospecific Antibody
18%
Mouse
23%
Mucin
10%
Neutralizing Antibody
34%
Normal Human
13%
Omicron Coronavirus Variant
31%
Photodynamics
20%
Salmonella Enterica Serovar Typhimurium
10%
Secretion (Process)
29%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Small Intestine
10%
Streptococcus Pneumoniae
10%
Symbiosis
11%
Systemic Autoimmune Disease
10%
Systemic Lupus Erythematosus
10%
T Cell
61%
T-Helper Cell
11%
Transcription Factors
30%
Vaccination Policy
14%
Vaccine Efficacy
76%
Keyphrases
Adaptive Immunity
12%
Booster Dose
11%
Breakthrough Cases
20%
Cefepime
13%
Cellular Response
17%
Chile
34%
Chilean
12%
Commensal Microbiota
12%
CoronaVac
62%
COVID-19
60%
Dendritic Cells
20%
Flow Cytometry
12%
Fold Increase
11%
Group 3 Innate Lymphoid Cells
24%
Host Cell
11%
Humoral Immune Response
12%
Humoral Response
14%
ILC3
61%
Immune Cells
14%
Immune Response
61%
Immunization Schedule
12%
Immunogenicity
30%
Immunoglobulin
20%
Inactivated SARS-CoV-2 Vaccine
16%
Inactivated Vaccine
23%
Interferon-α (IFN-α)
19%
Intestinal Immunity
12%
Intestinal mucosa
13%
Intestinal Tract
14%
Klebsiella Pneumoniae (K. pneumoniae)
19%
Lymphoid Tissue
22%
Lymphoid Tissue Inducer
18%
Mutualism
11%
Neutralizing Antibodies
41%
Neutralizing Capacity
19%
Omicron Variant
16%
Phase III Clinical Trial
20%
Photosensitizer
12%
Ru(II) Complexes
11%
Second Dose
18%
Serovars
17%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
15%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
42%
Synergistic Effect
13%
T Cells
33%
Tissue-resident
12%
Transcription Factor
23%
Two-dose
21%
Vaccination
11%
Variants of Concern
20%
